Gemcitabine and liposomal doxorubicin in the salvage treatment of ovarian cancer: updated results and long-term survival (Q46564227)

23 December 2017

title

Gemcitabine and liposomal doxorubicin in the salvage treatment of ovarian cancer: updated results and long-term survival (English)

1 reference

23 December 2017

1 reference

1 reference

6

1 reference

23 December 2017

Giovanni Scambia

12

object named as

Giovanni Scambia

1 reference

23 December 2017

author name string

Gabriella Ferrandina

1

1 reference

23 December 2017

Ida Paris

2

1 reference

23 December 2017

Manuela Ludovisi

3

1 reference

23 December 2017

Giuseppe D'Agostino

4

1 reference

23 December 2017

Antonia Testa

5

1 reference

23 December 2017

Mariangela Zanghi

7

1 reference

23 December 2017

Salvatore Pisconti

8

1 reference

23 December 2017

Giuseppa Pezzella

9

1 reference

23 December 2017

Vincenzo Adamo

10

1 reference

23 December 2017

Enrico Breda

11

1 reference

23 December 2017

language of work or name

English

0 references

publication date

1 August 2005

1 reference

23 December 2017

published in

Gynecologic Oncology

1 reference

23 December 2017

volume

98

1 reference

23 December 2017

issue

2

1 reference

23 December 2017

page(s)

267-273

1 reference

23 December 2017

Advanced epithelial ovarian cancer: 1998 consensus statements

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.04.018

7 January 2021

Cancer statistics, 2003.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.04.018

Phase 2 trial of single-agent gemcitabine in platinum-paclitaxel refractory ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.04.018

Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.04.018

Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.04.018

Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.04.018

Part II: chemotherapy for epithelial ovarian cancer-treatment of recurrent disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.04.018

Randomised controlled trial comparing single agent paclitaxel vs epidoxorubicin plus paclitaxel in patients with advanced ovarian cancer in early progression after platinum-based chemotherapy: an Italian Collaborative Study from the Mario Negri Inst

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.04.018

Role of chemotherapy in relapsed ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.04.018

Schedule-dependent interaction of doxorubicin, paclitaxel and gemcitabine in human breast cancer cell lines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.04.018

Induction of apoptosis using 2′,2′difluorodeoxycytidine (gemcitabine) in combination with antimetabolites or anthracyclines on malignant lymphatic and myeloid cells. Antagonism or synergism depends on incubation schedule and origin of neoplastic

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.04.018

A phase I study of gemcitabine and epirubicin for the treatment of platinum-resistant or refractory advanced ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.04.018

Treatment of recurrent platinum resistant ovarian or peritoneal cancer with gemcitabine and doxorubicin: A phase I/II trial of the Puget Sound Oncology Consortium (PSOC 1602).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.04.018

Phase I study of gemcitabine and liposomal doxorubicin in relapsed ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.04.018

Phase II study of liposomal doxorubicin and gemcitabine in the salvage treatment of ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.04.018

Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.04.018

Use of hematopoietic colony-stimulating factors: the American Society of Clinical Oncology survey. The Health Services Research Committee of the American Society of Clinical Oncology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.04.018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.04.018

Nonparametric Estimation from Incomplete Observations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.04.018

Phase II study of gemcitabine in recurrent platinum-and paclitaxel-resistant ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.04.018

Gemcitabine as a single-agent treatment for ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.04.018

Treatment of relapsed carcinoma of the ovary with single-agent paclitaxel following exposure to paclitaxel and platinum employed as initial therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.04.018

Is there a "best" choice of second-line agent in the treatment of recurrent, potentially platinum-sensitive ovarian cancer?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.04.018

Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.04.018

Phase II Study of Pegylated Liposomal Doxorubicin in Heavily Pretreated Epithelial Ovarian Cancer Patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.04.018

Oral dexamethasone attenuates Doxil-induced palmar-plantar erythrodysesthesias in patients with recurrent gynecologic malignancies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.04.018

The effect of regional cooling on toxicity associated with intravenous infusion of pegylated liposomal doxorubicin in recurrent ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.04.018

Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.04.018

10.1016/J.YGYNO.2005.04.018

7 January 2021

Identifiers

DOI

1 reference

23 December 2017

release_d2n7hfi6xvf4dajovvkrkndwa4

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/d2n7hfi6xvf4dajovvkrkndwa4

mapped directly with Wikidata item

24 November 2022

based on heuristic

PubMed ID

15975643

1 reference

23 December 2017